439 related articles for article (PubMed ID: 18665159)
21. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy.
Ito M; Ehara Y; Li J; Inada K; Ohno K
Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975
[TBL] [Abstract][Full Text] [Related]
22. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
[TBL] [Abstract][Full Text] [Related]
23. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
24. Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin/utrophin double knockout mice.
Xin C; Chu X; Wei W; Kuang B; Wang Y; Tang Y; Chen J; You H; Li C; Wang B
Hum Mol Genet; 2021 Jun; 30(14):1349-1359. PubMed ID: 33987645
[TBL] [Abstract][Full Text] [Related]
25. Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice.
Zhou L; Rafael-Fortney JA; Huang P; Zhao XS; Cheng G; Zhou X; Kaminski HJ; Liu L; Ransohoff RM
J Neurol Sci; 2008 Jan; 264(1-2):106-11. PubMed ID: 17889902
[TBL] [Abstract][Full Text] [Related]
26. Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin.
Li D; Bareja A; Judge L; Yue Y; Lai Y; Fairclough R; Davies KE; Chamberlain JS; Duan D
J Cell Sci; 2010 Jun; 123(Pt 12):2008-13. PubMed ID: 20483958
[TBL] [Abstract][Full Text] [Related]
27. Utrophin haploinsufficiency does not worsen the functional performance, resistance to eccentric contractions and force production of dystrophic mice.
Boulanger Piette A; Hamoudi D; Marcadet L; Kyomi Labelle F; Ovidiu David R; Bossé S; Argaw A; Frenette J
PLoS One; 2018; 13(6):e0198408. PubMed ID: 29879154
[TBL] [Abstract][Full Text] [Related]
28. Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice.
Wang B; Li J; Fu FH; Xiao X
J Orthop Res; 2009 Apr; 27(4):421-6. PubMed ID: 18973234
[TBL] [Abstract][Full Text] [Related]
29. Expression of full-length utrophin prevents muscular dystrophy in mdx mice.
Tinsley J; Deconinck N; Fisher R; Kahn D; Phelps S; Gillis JM; Davies K
Nat Med; 1998 Dec; 4(12):1441-4. PubMed ID: 9846586
[TBL] [Abstract][Full Text] [Related]
30. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.
Vulin A; Barthélémy I; Goyenvalle A; Thibaud JL; Beley C; Griffith G; Benchaouir R; le Hir M; Unterfinger Y; Lorain S; Dreyfus P; Voit T; Carlier P; Blot S; Garcia L
Mol Ther; 2012 Nov; 20(11):2120-33. PubMed ID: 22968479
[TBL] [Abstract][Full Text] [Related]
31. Second-generation compound for the modulation of utrophin in the therapy of DMD.
Guiraud S; Squire SE; Edwards B; Chen H; Burns DT; Shah N; Babbs A; Davies SG; Wynne GM; Russell AJ; Elsey D; Wilson FX; Tinsley JM; Davies KE
Hum Mol Genet; 2015 Aug; 24(15):4212-24. PubMed ID: 25935002
[TBL] [Abstract][Full Text] [Related]
32. Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice.
Amenta AR; Yilmaz A; Bogdanovich S; McKechnie BA; Abedi M; Khurana TS; Fallon JR
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):762-7. PubMed ID: 21187385
[TBL] [Abstract][Full Text] [Related]
33. Expression and localization of protein inhibitor of neuronal nitric oxide synthase in Duchenne muscular dystrophy.
Guo Y; Petrof BJ; Hussain SN
Muscle Nerve; 2001 Nov; 24(11):1468-75. PubMed ID: 11745948
[TBL] [Abstract][Full Text] [Related]
34. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.
Gutpell KM; Hrinivich WT; Hoffman LM
PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927
[TBL] [Abstract][Full Text] [Related]
35. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice.
Gregorevic P; Allen JM; Minami E; Blankinship MJ; Haraguchi M; Meuse L; Finn E; Adams ME; Froehner SC; Murry CE; Chamberlain JS
Nat Med; 2006 Jul; 12(7):787-9. PubMed ID: 16819550
[TBL] [Abstract][Full Text] [Related]
36. iNOS expression in dystrophinopathies can be reduced by somatic gene transfer of dystrophin or utrophin.
Louboutin JP; Rouger K; Tinsley JM; Halldorson J; Wilson JM
Mol Med; 2001 May; 7(5):355-64. PubMed ID: 11474581
[TBL] [Abstract][Full Text] [Related]
37. Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice.
van Putten M; Hulsker M; Young C; Nadarajah VD; Heemskerk H; van der Weerd L; 't Hoen PA; van Ommen GJ; Aartsma-Rus AM
FASEB J; 2013 Jun; 27(6):2484-95. PubMed ID: 23460734
[TBL] [Abstract][Full Text] [Related]
38. Constitutive properties, not molecular adaptations, mediate extraocular muscle sparing in dystrophic mdx mice.
Porter JD; Merriam AP; Khanna S; Andrade FH; Richmonds CR; Leahy P; Cheng G; Karathanasis P; Zhou X; Kusner LL; Adams ME; Willem M; Mayer U; Kaminski HJ
FASEB J; 2003 May; 17(8):893-5. PubMed ID: 12670877
[TBL] [Abstract][Full Text] [Related]
39. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
40. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.
Cerletti M; Negri T; Cozzi F; Colpo R; Andreetta F; Croci D; Davies KE; Cornelio F; Pozza O; Karpati G; Gilbert R; Mora M
Gene Ther; 2003 May; 10(9):750-7. PubMed ID: 12704413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
